OBR Daily Commentary - ESMO / ECC Conference Coverage

forumImage

Oncologists Demand More Education On The Use Of Biosimilars: ESMO Takes Action

(ESMO 2018 Congress) Oct 20, 2018 - Biological medicines are responsible for some of the most promising innovations in cancer treatment, including immunotherapy, targeted drugs and vaccines – but they are also expensive.

Stephen Lillard (Posted: October 25, 2018)

quotesIt’s becoming overwhelming the ad on with the immunotherapy is in biologicals. Need to go forward rapidly and reduced cost.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Roche Lands Tecentriq Trial Win, Still Trails Merck In Lung Cancer

(Reuters) Oct 22, 2018 - Roche’s Tecentriq plus chemotherapy boosted lung cancer patients’ survival by nearly five months, study data released on Monday showed, underscoring benefits of the Swiss group’s immunotherapy but still leaving it trailing a rival’s drug.

H. Jack West, MD (Posted: October 22, 2018)

quotesResults of IMpower130 are certainly favorable and positive for the carbo/nab-paclitaxel/atezolizumab combination, but I think they are not going to displace carbo/pemetrexed/pembrolizumab as a regimen of choice in this setting based on the KEYNOTE-189 trial. Carbo/pemetrexed is a more commonly used and favored chemotherapy backbone for this population, and the results with IMpower130 cannot be considered superior to those of KEYNOTE-189. It is notable that the patients with EGFR mutation or ALK+ NSCLC did not appear to benefit from the chemotherapy/immunotherapy combination, supporting the possibility that the benefit seen in this subset of patients in arm B of the IMpower150 trial (receiving carbo/paclitaxel/bevacizumab/atezolizumab) over the control arm of carbo/pac/bev alone may be a function of the inclusion of bevacizumab. We await further data to clarify this hypothesis. NOTE: I am an author of the IMpower130 abstract/presentation.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...